€5 Million for Venture Challenge Alumnus Prolira

In 2014, Prolira participated in the Venture Challenge as a start-up. Now, years later, the announcement has been made that several parties under which Borski fund, ROM Utrecht Region, Holland Capital, Health Innovations and Oost NL together invest €5 million in Prolira BV to further help hospital departments improve patient care in the field of acute brain failure (acute encephalopathy and delirium).

Prolira provides the world’s first objective brain state monitor (DeltaScan®) to hospitals, as well as data driven support that quantifies the positive impact of DeltaScan implementation in patient care protocols. DeltaScan® is a revolutionary CE marked (and pending FDA clearance) medical device that objectively monitors the brain state of patients, using breakthrough EEG technology and smart AI algorithms. Actively using the patient’s brain state information is essential for making better informed medical decision and realising improved patient care with better outcomes.

“Monitoring the brain state of patients is as important as monitoring other vital organs like the heart or the lungs. Every year, as many as 20 million hospital patients are at risk of acute brain failure in Europe and the US. This large group of patients needs the care improvement that Prolira offers”, says Annemarie Willems, Chief Business Development/Founder of Prolira.

With DeltaScan® acute encephalopathy and delirium are detected in more patients and earlier, providing healthcare care professionals timely information to improve their care processes. This is good news for all stakeholders in the healthcare system, as reduced length of hospital stay, increased hospital patient capacity and significant cost reduction on hospital department level can be achieved.

Read more about how Prolira came to be and its objectives here.

Source: ROM Utrecht Region

Investment

‹ News overview